Dem senator's daughter could face Congress over EpiPen price hike
© Mylan

Sen. Joe ManchinJoseph (Joe) ManchinGOP senator: Gun control debate 'hasn't changed much at all' back home What the gun safety debate says about Washington Sunday shows - Recession fears dominate MORE's (D-W.Va.) daughter may have to explain to Congress why her company hiked up the price of EpiPens, Bloomberg News is reporting

Heather Bresch serves as the CEO of Mylan, which acquired EpiPen in 2007. Since then, the device's cost has increased 400 percent, from $57 to more than $500.

Bresch could be called to Capitol Hill next month to explain the price increase, according to Bloomberg.

Members of Congress have expressed concern over the price increase for the EpiPen, a lifesaving injection for people suffering from severe allergic reactions.

“I am deeply concerned by this significant price increase for a product that has been on the market for more than three decades, and by Mylan’s failure to publicly explain the recent cost increase, which places a significant burden on parents, schools and other purchasers of the EpiPen,” Sen. Mark WarnerMark Robert WarnerFacebook users in lawsuit say company failed to warn them of known risks before 2018 breach New intel chief inherits host of challenges Overnight Defense: US, Russia tensions grow over nuclear arms | Highlights from Esper's Asia trip | Trump strikes neutral tone on Hong Kong protests | General orders ethics review of special forces MORE (D-Va.) said Tuesday in a statement.

In a letter Monday, Sen. Richard Blumenthal (D-Conn.), a member of the Senate Judiciary Committee, asked Bresch to explain the "shocking price increases."

He declined during an interview on Tuesday to comment about the possibility that Bresch would come before Congress.

Rep. Grace Meng (D-N.Y.), meanwhile, is calling for a full committee hearing on the cost of EpiPens. In a letter to the chairman and ranking member of the House Oversight and Government Reform Committee on Monday, Meng relayed her concerns over the drug price hike.

As of Tuesday afternoon, no hearing was scheduled on the issue, a spokeswoman for committee Chairman Jason ChaffetzJason ChaffetzHouse Oversight panel demands DeVos turn over personal email records The Hill's Morning Report - Presented by JUUL Labs - Trump attack on progressive Dems draws sharp rebuke GOP senators decline to criticize Acosta after new Epstein charges MORE told Bloomberg. The spokeswoman offered no comment beyond that.

Elijah Cummings, the top Democrat on the Oversight Committee, called the price hike a "financial burden on those who desperately need this drug" and expressed a desire for "an investigation of this issue and for the Committee to hold a hearing in September."